Project Grant R41AI134428

This $782,178 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop new antifungal agents targeting the sterylglucosidase (SGL1/SGLA) enzyme in fungal pathogens. The research aims to apply structural biology, computational drug design, and medicinal chemistry approaches to identify and optimize novel SGL1/SGLA inhibitors that could serve as effective...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,326,630 to Duke University to conduct research on improving treatment strategies for talaromycosis, a deadly fungal infection prevalent in Southeast Asia. The key objectives are to: 1) Determine if a single high-dose of liposomal amphotericin B (LAMB) is superior to the standard 14-day course of amphotericin B...

This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover and develop new, more potent antifungal therapies for treating invasive fungal infections such as cryptococcosis, candidiasis, and aspergillosis. The funding will support the continued screening of chemical libraries to identify lead compounds that selectively inhibit the fungal ceramide synthase 1...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $170,000.00 in funding to Prokaryotics Incorporated for a 2-year period from February 1, 2025 to January 31, 2027. The funding supports research to develop novel antifungal therapeutics that target the glycosylphosphatidylinositol (GPI) biosynthesis pathway in fungi. The key objectives are to conduct structural...

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $616,588 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the fungal pathogen Cryptococcus neoformans, which is the leading cause of fungal meningitis globally. The research aims to develop a high-precision phenotypic map of the pathogen's genes in order to better understand...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation, conduct toxicological and stability studies, and prepare an Investigational New Drug (IND) application...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to develop novel therapeutic strategies for treating mucormycosis, a deadly invasive fungal infection. The $750,815 award, effective March 25, 2025 through February 28, 2030, will be carried out by the University of Maryland, Baltimore. The key objectives of this research project are to: 1) Examine the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $2,917,725.00 to The Regents of the University of Colorado for the development of novel antifungal agents to treat coccidioidomycosis, a serious fungal infection endemic to the Southwestern U.S. The key objectives are to perform structure-activity relationship studies on a lead natural product candidate, investigate its mechanism of action, and...

This $642,775 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to accelerate the discovery of novel antifungal peptides using one-bead one-compound (OBOC) combinatorial technology. The University of California, Davis will conduct high-throughput screening of chemically synthesized peptide libraries to identify membrane-active antifungal peptides that can...